The bioartificial kidney (BAK) aims at improving dialysis by developing 'living membranes' for cells-aided removal of uremic metabolites. Here, unique human conditionally immortalized proximal tubule epithelial cell (ciPTEC) monolayers were cultured on biofunctionalized MicroPES (polyethersulfone) hollow fiber membranes (HFM) and functionally tested using microfluidics. Tight monolayer formation was demonstrated by abundant zonula occludens-1 (ZO-1) protein expression along the tight junctions of matured ciPTEC on HFM. A clear barrier function of the monolayer was confirmed by limited diffusion of FITC-inulin. The activity of the organic cation transporter 2 (OCT2) in ciPTEC was evaluated in real-time using a perfusion system by confocal mi...
DMPK (Drug Metabolism and Pharmacokinetics) studies are essential for drug development but 90% of po...
Increasing incidence of renal pathology in the western world calls for innovative research for the d...
The development of a biotechnological platform for the removal of waste products (e.g. uremic toxins...
The bioartificial kidney (BAK) aims at improving dialysis by developing 'living membranes' for cells...
The limited removal of metabolic waste products in dialyzed kidney patients leads to high morbidity ...
The development of cell based bioartificial kidney (BAK) could improve existing dialysis therapies f...
The need for improved renal replacement therapies has stimulated innovative research for the develop...
The need for improved renal replacement therapies has stimulated innovative research for the develop...
The accumulation of protein-bound toxins in dialyzed patients is strongly associated with their high...
Patients with end-stage kidney disease (ESKD) suffer from high levels of protein-bound uremic toxins...
DMPK (Drug Metabolism and Pharmacokinetics) studies are essential for drug development but 90% of po...
Increasing incidence of renal pathology in the western world calls for innovative research for the d...
The development of a biotechnological platform for the removal of waste products (e.g. uremic toxins...
The bioartificial kidney (BAK) aims at improving dialysis by developing 'living membranes' for cells...
The limited removal of metabolic waste products in dialyzed kidney patients leads to high morbidity ...
The development of cell based bioartificial kidney (BAK) could improve existing dialysis therapies f...
The need for improved renal replacement therapies has stimulated innovative research for the develop...
The need for improved renal replacement therapies has stimulated innovative research for the develop...
The accumulation of protein-bound toxins in dialyzed patients is strongly associated with their high...
Patients with end-stage kidney disease (ESKD) suffer from high levels of protein-bound uremic toxins...
DMPK (Drug Metabolism and Pharmacokinetics) studies are essential for drug development but 90% of po...
Increasing incidence of renal pathology in the western world calls for innovative research for the d...
The development of a biotechnological platform for the removal of waste products (e.g. uremic toxins...